• University of Sydney Given  $3.75M Grant to Study Personalized Ovarian Cancer Treatments
  • Myriad Asks FDA to Approve myChoice CDx to Find Potential Lynparza Candidates
  • Analysis of Cells in Fallopian Tube Can Help Classify Ovarian Cancer Subtypes, Study Says
  • Checkpoint Inhibitor Combination Well-tolerated, Effective in Ovarian Cancer Patients, Phase 1b Trial Shows
  • New Trial Data Continue to Support DPX-Survivac in Treating Advanced Ovarian Cancer
  • France Adds Rubraca for Relapsed Platinum-sensitive Ovarian Cancer to Reimbursed Treatments
  • New Progress Made in Developing Bio-ink for 3-D Printing Functional Human Ovaries, Researchers Report
  • Nami Developing Targeted Nanoparticle Therapy for Advanced Forms of Ovarian Cancer
  • Clinical Trial of DNA Decoy to Make Ovarian Cancer’s Zejula More Effective Set to Open
  • First Patient Dosed in Phase 1 Trial of SY-5609 for OC, Other Solid Tumors, Syros Announces
  • Cycle for Survival Kicks Off Fundraising Events With Goal to Surpass Last Year’s $42M
  • Mereo Licenses Navicixizumab to Oncologie for Worldwide Development, Commercialization